MoneyWorks4Me

Alembic Pharmaceuticals informs about disclosure

09 Oct 2024 Evaluate
Alembic Pharmaceuticals has informed that the Company has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oncology (Injectable and Oral Solid) Formulation Facility (F-2) located at Panelav. The inspection was successfully completed without any Form 483 observation. The inspection was conducted from 7th October, 2024 to 8th October, 2024.

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..